CClinicalTrials.gg
Not yet recruitingNCT07015359Updated Jun 11, 2025

Renal Functions in Preeclamptic Pregnant Women Using Neutrophil Gelatinase-associated Lipocalin (NGAL) and Standard Renal Function Tests

An observational study in Anesthesia, Spinal Aneshtesia and Acute Kidney Failure, sponsored by Nihan Aydin Guzey. Not yet recruiting at 1 site in Turkey. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-06-11.

Sponsored by Nihan Aydin Guzey · Observational

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
46
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Acute kidney injury (AKI) is a significant postoperative complication. Risk factors for AKI include impaired renal perfusion, decreased functional renal reserve, as well as advanced age, peripheral arterial disease, diabetes mellitus, renovascular disease and congestive heart failure. Mean arterial pressure (MAP) below 55-60 mmHg has been associated with postoperative AKI. Traditional diagnostic criteria for AKI include increased serum creatinine levels and oliguria. However, creatinine levels do not rise until more than half of renal function is lost. Serum and urine NGAL levels rise earlier-within 24-48 hours-making it a promising early biomarker.

In our study, hypotension is defined as systolic blood pressure \<100 mmHg or a >30% decrease in MAP. Patients requiring ephedrine under these conditions will be evaluated as the hypotension group and compared with non-hypotensive patients in terms of NGAL, BUN (blood urea nitrogen), creatinine, and GFR (Glomerular Filtration Rate) values at baseline and at the 4th postoperative hour.

Read the detailed description

All patients were informed about the study in the preoperative period and written informed consent was obtained before the procedure. The following data were recorded: age, sex, weight, height, BMI (Body Mass Index), comorbidities, regular medications, ASA (American Society of Anesthesiologists) classification, gestational age, history of preeclampsia in previous pregnancies, hemodynamic values and laboratory results. After being admitted to the cesarean operating room, patients were monitored according to the ASA guidelines using standard monitoring methods (non-invasive arterial blood pressure measurements at 2-minute intervals, 3-lead ECG (Electrocardiogram) and pulse oximetry). A peripheral intravenous line was established via the dorsum of the hand and Ringer's lactate was infused at a rate of 10 mL/kg/h. All patients received oxygen via nasal cannula at a rate of 3-4 L/min.

Blood samples were collected from the patients before spinal anesthesia and at the 4th postoperative hour. The samples were centrifuged at 4000×g for 10 minutes in the biochemistry laboratory and then transferred into Eppendorf tubes and stored at -80°C in a deep freezer until the day of analysis. NGAL levels were measured using an ELISA (Enzyme-Linked ImmunoSorbent Assay) method with a commercial kit (USCN, China) at the Biochemistry Laboratory of Ankara Bilkent City Hospital. Each sample was measured in duplicate, and the mean values were used for evaluation. The intra-assay and inter-assay coefficients of variation (CV%) for the kit were determined to be \<10% and \<12%, respectively. At the 4th postoperative hour, blood samples were also analyzed for BUN, creatinine, and GFR levels, which were recorded accordingly.

02

Conditions studied

  • Anesthesia
  • Spinal Aneshtesia
  • Acute Kidney Failure
  • Spinal Anesthesia Induced Hypotension
  • Preeclampsia (PE)

Keywords

  • Preeclampsia
  • Hypotension
  • NGAL
  • Creatinine
  • AKI
03

In context

Pre-Eclampsia

882 studies on the registry are indexed under Pre-Eclampsia; 237 are open to participants now.

This study's planned enrollment of 46 is below the median of 163 across 380 observational studies indexed under Pre-Eclampsia.

Browse Pre-Eclampsia studies →

Lead sponsor

This is the only study on the registry with Nihan Aydin Guzey as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Preeclamptic pregnant women aged 18 to 45 years, classified as ASA II-III, who volunteered to participate, were scheduled for cesarean section, and received spinal anesthesia were included in the study.

Inclusion criteria

  • Patients classified as ASA physical status II-III
  • Pregnant women aged 18-45 years, diagnosed with preeclampsia and scheduled for elective cesarean section, will be included in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients who are unable to read, understand, or sign the informed consent form
  • Patients with a diagnosed renal disease
  • Patients who do not wish to participate in the study
  • Patients with ASA physical status greater than III
  • Patients younger than 18 or older than 45 years
  • Patients requiring sedation or undergoing general anesthesia
  • Patients with cardiac instability
  • Patients with known arrhythmias
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
46 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • CASE GROUP

    During the operation, heart rate (HR) and peripheral oxygen saturation (SpO₂) were continuously monitored. Systolic arterial pressure (SAP), diastolic arterial pressure (DAP), and mean arterial pressure (MAP) were measured and recorded every 2 minutes for the first 15 minutes, then every 5 minutes thereafter. Hypotension was defined as a ≥30% decrease in MAP from baseline or systolic blood pressure \<100 mmHg. Patients who developed hypotension within the first four measurements were included in the hypotension group. Patients who developed hypotension in later measurements were excluded from the study to avoid confusion with bleeding-related hypotension. A 5 mg bolus of ephedrine was administered to raise the MAP to 80% or more of the baseline level within 60 seconds. Surgical duration, amount of fluids administered, duration and number of hypotensive episodes, total dose of ephedrine, estimated blood loss, use of additional uterotonics or tranexamic acid, neonatal weight, and Apgar.

  • CONTROL GROUP

    During the operation, the patient's heart rate (HR) and peripheral oxygen saturation (SpO₂) were continuously monitored. Systolic arterial pressure (SAP), diastolic arterial pressure (DAP), and mean arterial pressure (MAP) were measured and recorded every 2 minutes for the first 15 minutes, and then every 5 minutes thereafter. Patients whose MAP did not decrease by 30% or more from the baseline value were considered the control group

06

What researchers measure

Primary outcomes

  1. ID: TABED 2/170/2024 Change in Plasma NGAL Levels Before and After Spinal Anesthesia

    To assess whether spinal anesthesia-induced hypotension in preeclamptic patients leads to early kidney injury, based on changes in plasma NGAL (neutrophil gelatinase-associated lipocalin) levels.

    Time frame: Before spinal anesthesia and at postoperative 4th hour

Secondary outcomes

  1. Renal Function Parameters Post-Spinal Anesthesia

    Evaluation of postoperative serum urea levels to assess renal function in the early postoperative period.

    Time frame: Postoperative 4th hour

  2. Comparative Timing of NGAL and Creatinine in Detecting AKI

    To compare the timing of elevation between plasma NGAL and serum creatinine for early detection of acute kidney injury in preeclamptic patients.

    Time frame: NGAL measured before and 4 hours after anesthesia; creatinine at 4 hours

  3. Intraoperative Hemodynamic Monitoring

    Measurement of hemodynamic parameter systolic arterial pressure \[SAP\] at specified time points during the operation to evaluate the cardiovascular effects of spinal anesthesia in preeclamptic patients.

    Time frame: Measurements recorded at 2, 4, 6, 8, 10, 12, 14, 20, 25, 30, 35, 40, 50, and 55 minutes after spinal anesthesia initiation.

  4. Intraoperative Hemodynamic Monitoring

    Measurement of hemodynamic parameter diastolic arterial pressure \[DAP\] at specified time points during the operation to evaluate the cardiovascular effects of spinal anesthesia in preeclamptic patients.

    Time frame: Measurements recorded at 2, 4, 6, 8, 10, 12, 14, 20, 25, 30, 35, 40, 50, and 55 minutes after spinal anesthesia initiation.

  5. Intraoperative Hemodynamic Monitoring

    Measurement of hemodynamic parameter mean arterial pressure \[MAP\] at specified time points during the operation to evaluate the cardiovascular effects of spinal anesthesia in preeclamptic patients.

    Time frame: Measurements recorded at 2, 4, 6, 8, 10, 12, 14, 20, 25, 30, 35, 40, 50, and 55 minutes after spinal anesthesia initiation.

  6. Intraoperative Hemodynamic Monitoring

    Measurement of hemodynamic parameter heart rate \[HR\] at specified time points during the operation to evaluate the cardiovascular effects of spinal anesthesia in preeclamptic patients.

    Time frame: Measurements recorded at 2, 4, 6, 8, 10, 12, 14, 20, 25, 30, 35, 40, 50, and 55 minutes after spinal anesthesia initiation.

  7. Intraoperative Hemodynamic Monitoring

    Measurement of hemodynamic parameter oxygen saturation \[SpO₂\] at specified time points during the operation to evaluate the cardiovascular effects of spinal anesthesia in preeclamptic patients.

    Time frame: Measurements recorded at 2, 4, 6, 8, 10, 12, 14, 20, 25, 30, 35, 40, 50, and 55 minutes after spinal anesthesia initiation.

  8. Renal Function Parameters Post-Spinal Anesthesia

    Evaluation of postoperative serum creatinine levels to assess renal function in the early postoperative period.

    Time frame: Postoperative 4th hour

  9. Renal Function Parameters Post-Spinal Anesthesia

    Evaluation of postoperative eGFR levels to assess renal function in the early postoperative period.

    Time frame: Postoperative 4th hour

Other outcomes

  1. Incidence of Spinal Anesthesia-Related Hypotension

    Number and percentage of patients who experience hypotension (defined as a \>20% decrease from baseline systolic blood pressure) following spinal anesthesia.

    Time frame: Within the first 30 minutes after spinal anesthesia

  2. Total Intraoperative Vasopressor Requirement

    otal dose of vasopressors (e.g., ephedrine or phenylephrine) administered to treat spinal-induced hypotension.

    Time frame: Intraoperative period

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07015359
Lead sponsor
Nihan Aydin Guzey
Collaborators
Ankara City Hospital Bilkent
Responsible party
Nihan Aydin Guzey (Assoc.Prof. MD, Ankara City Hospital Bilkent) — Sponsor-investigator
First posted
Jun 11, 2025
Start date
Jun 8, 2025 (estimated)
Primary completion
Sep 22, 2025 (estimated)
Completion
Oct 20, 2025 (estimated)
Last update
Jun 11, 2025

Study contacts

Cahide Çağlayan, Dr
Contact
cahide.gulsen@hotmail.com
+905547542106
Nihan Aydın Güzey
Contact
nihanaydinguzey@gmail.com
+905056496231
Nihan Aydın Güzey
principal investigator · Ankara City Hospital Bilkent

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion